サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1363809

イマチニブ医薬品の世界市場規模調査＆予測、剤形別、用途タイプ別、地域別分析、2023-2030年

Global Imatinib Drug Market Size study & Forecast, by Drug Formulation by Application Type and Regional Analysis, 2023-2030
出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
イマチニブ医薬品の世界市場規模調査＆予測、剤形別、用途タイプ別、地域別分析、2023-2030年
出版日: 2023年10月04日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

イマチニブはある種のがんの治療に使用されます。

チロシンキナーゼ阻害薬（TKI）として知られる薬剤のクラスに属します。イマチニブは、特定のがん細胞によって産生されるチロシンキナーゼと呼ばれる異常なタンパク質を特異的に標的とし、その活性を阻害します。イマチニブは主に、異常な白血球の過剰産生を特徴とする血液がんの一種である慢性骨髄性白血病（CML）の治療に用いられます。また、消化管に発生する腫瘍の一種である消化管間質腫瘍（GIST）の治療にも処方されることがあります。イマチニブ医薬品市場は、慢性骨髄性白血病（CML）や消化管間質腫瘍（GIST）の発生率の増加、標的薬物療法に対する需要の増加などの要因により拡大しています。

イマチニブはCMLの治療で顕著な成功を収め、高い奏効率と長期予後の改善につながっています。したがって、慢性骨髄性白血病の罹患率の増加が市場成長の原動力となっています。National Library of Medicineによると、世界中の慢性骨髄性白血病（CML）の有病率は2020年には112,000人であり、2030年には144,000人、2040年には167,000人、2050年には181,000人に増加すると予測されています。世界中で慢性骨髄性白血病の罹患率が上昇していることが、市場成長の原動力となっています。さらに、ヘルスケア支出の増加とイマチニブ医薬品開発に関連する研究開発活動の活発化が、市場に有利な機会を生み出しています。しかし、イマチニブ医薬品の高コストと代替品の入手可能性が、2023～2030年の予測期間を通じて市場の成長を阻害しています。

イマチニブ薬の世界市場調査において考慮した主要地域は、アジア太平洋、北米、欧州、ラテンアメリカ、中東・アフリカです。北米は、主要市場プレイヤーの存在、薬剤の新興市場開拓、同地域におけるがん疾患の罹患率の上昇により、2022年の市場を独占しました。一方、アジア太平洋地域は、同地域におけるがんの罹患率の上昇、創薬活動への投資の増加、創薬活動を促進するための政府のイニシアチブの高まりなどの要因により、著しい成長を示しています。

本調査の目的は、近年のさまざまなセグメントと国の市場規模を明らかにし、今後数年間の市場規模を予測することです。本レポートは、調査対象国における業界の質的・量的側面の両方を盛り込むよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題などの重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢と市場情勢の詳細な分析とともに、利害関係者が投資するためのミクロ市場における潜在的な機会も組み込んでいます。.

目次

第1章 エグゼクティブサマリー

第2章 世界のイマチニブ医薬品市場の定義と範囲

  • 調査目的
  • 市場の定義と範囲
    • 産業の進化
    • 調査範囲
  • 調査対象年
  • 通貨換算レート

第3章 世界のイマチニブ薬市場力学

  • イマチニブ薬市場の影響分析（2020-2030年）
    • 市場促進要因
      • 慢性骨髄性白血病（CML）および消化管間質腫瘍（GIST）の発生率の増加
      • 標的薬治療に対する需要の増加
    • 市場の課題
      • イマチニブ製剤の高コスト
      • 代替品の入手可能性
    • 市場機会
      • ヘルスケア支出の増加
      • イマチニブに関する研究開発活動の増加

第4章 世界のイマチニブ医薬品市場産業分析

  • ポーターの5フォースモデル
    • 供給企業の交渉力
    • 買い手の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
  • ポーターの5フォース影響分析
  • PEST分析
    • 政治
    • 経済
    • 社会
    • 技術
    • 環境
    • 法律
  • 主な投資機会
  • 主要成功戦略
  • COVID-19影響分析
  • 破壊的動向
  • 業界専門家の視点
  • アナリストの結論・提言

第5章 イマチニブ医薬品の世界市場：剤形別

  • 市場スナップショット
  • イマチニブ医薬品の世界市場：剤形別、実績 - ポテンシャル分析
  • イマチニブ薬の世界市場、剤形別推定・予測2020～2030年
  • イマチニブ薬市場、サブセグメント分析
    • カプセル剤
    • 錠剤

第6章 イマチニブ医薬品の世界市場：用途タイプ別

  • 市場スナップショット
  • イマチニブ医薬品の世界市場：用途タイプ別、実績 - ポテンシャル分析
  • イマチニブ製剤の世界市場、用途タイプ別推定・予測2020～2030年
  • イマチニブ医薬品市場、サブセグメント別分析
    • フィラデルフィア陽性慢性骨髄性白血病
    • 好酸球増多症候群（HES）
    • 骨髄異形成症候群（MDS）
    • 骨髄増殖性疾患（MPD）
    • 消化管間質腫瘍（GIST）
    • その他

第7章 イマチニブ医薬品の世界市場、地域分析

  • 主要国
  • 主な新興国
  • イマチニブ薬市場、地域別市場スナップショット
  • 北米
    • 米国
      • 剤形の推定・予測、2020～2030年
      • アプリケーションタイプの推定・予測、2020～2030年
    • カナダ
  • 欧州イマチニブ医薬品市場スナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • アジア太平洋イマチニブ医薬品市場スナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカのイマチニブ医薬品市場スナップショット
    • ブラジル
    • メキシコ
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • その他中東とアフリカ

第8章 競合情報

  • 主要企業のSWOT分析
  • 主要市場戦略
  • 企業プロファイル
    • Sun Pharmaceutical Industries Ltd.
      • 主要情報
      • 概要
      • 財務（データの入手可能性によります）
      • 製品概要
      • 最近の動向
    • Novartis AG
    • Dr. Reddy's Laboratories Ltd
    • Teva Pharmaceutical Industries Ltd.
    • Mylan N.V.
    • Cipla Inc
    • Apotex Inc
    • Sanofi S.A
    • Glenmark Pharmaceuticals Ltd.
    • Dongbao Pharmaceutical Co. Ltd.

第9章 調査プロセス

  • 調査プロセス
    • データマイニング
    • 分析
    • 市場推定
    • 検証
    • 出版
  • 調査属性
  • 調査前提条件
図表

LIST OF TABLES

  • TABLE 1. Global Imatinib Drug Market, report scope
  • TABLE 2. Global Imatinib Drug Market estimates & forecasts by Region 2020-2030 (USD Billion)
  • TABLE 3. Global Imatinib Drug Market estimates & forecasts by Drug Formulation 2020-2030 (USD Billion)
  • TABLE 4. Global Imatinib Drug Market estimates & forecasts by Application Type 2020-2030 (USD Billion)
  • TABLE 5. Global Imatinib Drug Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 6. Global Imatinib Drug Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 7. Global Imatinib Drug Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 8. Global Imatinib Drug Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 9. Global Imatinib Drug Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 10. Global Imatinib Drug Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 11. Global Imatinib Drug Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 12. Global Imatinib Drug Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 13. Global Imatinib Drug Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 14. Global Imatinib Drug Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 15. U.S. Imatinib Drug Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 16. U.S. Imatinib Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 17. U.S. Imatinib Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 18. Canada Imatinib Drug Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 19. Canada Imatinib Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 20. Canada Imatinib Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 21. UK Imatinib Drug Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 22. UK Imatinib Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 23. UK Imatinib Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 24. Germany Imatinib Drug Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 25. Germany Imatinib Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 26. Germany Imatinib Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 27. France Imatinib Drug Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 28. France Imatinib Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 29. France Imatinib Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 30. Italy Imatinib Drug Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 31. Italy Imatinib Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 32. Italy Imatinib Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 33. Spain Imatinib Drug Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 34. Spain Imatinib Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 35. Spain Imatinib Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 36. RoE Imatinib Drug Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 37. RoE Imatinib Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 38. RoE Imatinib Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 39. China Imatinib Drug Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 40. China Imatinib Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 41. China Imatinib Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 42. India Imatinib Drug Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 43. India Imatinib Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 44. India Imatinib Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 45. Japan Imatinib Drug Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 46. Japan Imatinib Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 47. Japan Imatinib Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 48. South Korea Imatinib Drug Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 49. South Korea Imatinib Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 50. South Korea Imatinib Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 51. Australia Imatinib Drug Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 52. Australia Imatinib Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 53. Australia Imatinib Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 54. RoAPAC Imatinib Drug Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 55. RoAPAC Imatinib Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 56. RoAPAC Imatinib Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 57. Brazil Imatinib Drug Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 58. Brazil Imatinib Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 59. Brazil Imatinib Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 60. Mexico Imatinib Drug Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 61. Mexico Imatinib Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 62. Mexico Imatinib Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 63. RoLA Imatinib Drug Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 64. RoLA Imatinib Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 65. RoLA Imatinib Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 66. Saudi Arabia Imatinib Drug Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 67. South Africa Imatinib Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 68. RoMEA Imatinib Drug Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 69. List of secondary sources, used in the study of global Imatinib Drug Market
  • TABLE 70. List of primary sources, used in the study of global Imatinib Drug Market
  • TABLE 71. Years considered for the study
  • TABLE 72. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

  • FIG 1. Global Imatinib Drug Market, research methodology
  • FIG 2. Global Imatinib Drug Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Imatinib Drug Market, key trends 2022
  • FIG 5. Global Imatinib Drug Market, growth prospects 2023-2030
  • FIG 6. Global Imatinib Drug Market, porters 5 force model
  • FIG 7. Global Imatinib Drug Market, pest analysis
  • FIG 8. Global Imatinib Drug Market, value chain analysis
  • FIG 9. Global Imatinib Drug Market by segment, 2020 & 2030 (USD Billion)
  • FIG 10. Global Imatinib Drug Market by segment, 2020 & 2030 (USD Billion)
  • FIG 11. Global Imatinib Drug Market by segment, 2020 & 2030 (USD Billion)
  • FIG 12. Global Imatinib Drug Market by segment, 2020 & 2030 (USD Billion)
  • FIG 13. Global Imatinib Drug Market by segment, 2020 & 2030 (USD Billion)
  • FIG 14. Global Imatinib Drug Market, regional snapshot 2020 & 2030
  • FIG 15. North America Imatinib Drug Market 2020 & 2030 (USD Billion)
  • FIG 16. Europe Imatinib Drug Market 2020 & 2030 (USD Billion)
  • FIG 17. Asia pacific Imatinib Drug Market 2020 & 2030 (USD Billion)
  • FIG 18. Latin America Imatinib Drug Market 2020 & 2030 (USD Billion)
  • FIG 19. Middle East & Africa Imatinib Drug Market 2020 & 2030 (USD Billion)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

目次

Imatinib drug is used to treat certain types of cancer. It belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs). Imatinib specifically targets and inhibits the activity of abnormal proteins called tyrosine kinases, which are produced by specific cancer cells. Imatinib is primarily used for the treatment of chronic myeloid leukemia (CML), a type of blood cancer characterized by the overproduction of abnormal white blood cells. It can also be prescribed for the treatment of gastrointestinal stromal tumors (GISTs), a type of tumor that occurs in the gastrointestinal tract. The Imatinib Drug market is expanding because of factors such as Increasing incidence of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs) and increase in demand for target drug therapy.

Imatinib has demonstrated remarkable success in the treatment of CML, leading to high response rates and improved long-term outcomes. Thus, Rising prevelance of chronic myeloid leukemia is driving the market growth. According to National Library of Medicine, The prevalence of chronic myeloid leukemia (CML) across the globe is 112,000 in year 2020, and it is projected to increase to 144,000 by year 2030, and 167,000 cased by year 2040 and 181,000 cases by year 2050. The rising prevelance of chronic myeloid leukemia across the globe is driving the market growth. In addition, rise in healthcare expenditure and increasing R&D activities related to imatinib drug development is creating a lucrative opportunity in the market. However, high cost of imatinib drug and availability of substitutes stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Imatinib Drug Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in year 2022 owing to presence of key market players, rising development of drug, rising prevelance of cancer disease in the region. Whereas Asia Pacific is witnessing a significant growth owing to factors such as rising prevelance of cancer in the region, rising investment in drug discovery activities, rising government initiatives for promoting drug development activities.

Major market player included in this report are:

  • Sun Pharmaceutical Industries Ltd.
  • Novartis AG
  • Dr. Reddy's Laboratories Ltd
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Cipla Inc
  • Apotex Inc
  • Sanofi S.A
  • Glenmark Pharmaceuticals Ltd.
  • Dongbao Pharmaceutical Co. Ltd.

Recent Developments in the Market:

  • In October 2021, Tenax Therapeutics, Inc. Announced that the FDA has reviewed and cleared its Investigational New Drug (IND) application for a novel formulation of imatinib.

Global Imatinib Drug Market Report Scope:

  • Historical Data: 2020 - 2021
  • Base Year for Estimation: 2022
  • Forecast period: 2023-2030
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: Drug Formulation, Application Type, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Drug Formulation offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Drug Formulation:

  • Capsules
  • Tablets

By Application Type:

  • Philadelphia Positive Chronic Myeloid Leukemia
  • Hyper-Eosinophilic Syndrome (HES)
  • Myelodysplastic Syndrome (MDS)
  • Myeloproliferative Diseases (MPD)
  • Gastrointestinal Stromal Tumors (GIST)
  • Others

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1. Imatinib Drug Market, by Region, 2020-2030 (USD Billion)
    • 1.2.2. Imatinib Drug Market, by Drug Formulation, 2020-2030 (USD Billion)
    • 1.2.3. Imatinib Drug Market, by Application Type, 2020-2030 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Imatinib Drug Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Imatinib Drug Market Dynamics

  • 3.1. Imatinib Drug Market Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing incidence of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs)
      • 3.1.1.2. Increase in demand for target drug therapy.
    • 3.1.2. Market Challenges
      • 3.1.2.1. High Cost of Imatinib Drug
      • 3.1.2.2. Availability of substitutes
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Rise in healthcare expenditure
      • 3.1.3.2. Increasing R&D activities related to imatinib.

Chapter 4. Global Imatinib Drug Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Imatinib Drug Market, by Drug Formulation

  • 5.1. Market Snapshot
  • 5.2. Global Imatinib Drug Market by Drug Formulation, Performance - Potential Analysis
  • 5.3. Global Imatinib Drug Market Estimates & Forecasts by Drug Formulation 2020-2030 (USD Billion)
  • 5.4. Imatinib Drug Market, Sub Segment Analysis
    • 5.4.1. Capsules
    • 5.4.2. Tablets

Chapter 6. Global Imatinib Drug Market, by Application Type

  • 6.1. Market Snapshot
  • 6.2. Global Imatinib Drug Market by Application Type, Performance - Potential Analysis
  • 6.3. Global Imatinib Drug Market Estimates & Forecasts by Application Type 2020-2030 (USD Billion)
  • 6.4. Imatinib Drug Market, Sub Segment Analysis
    • 6.4.1. Philadelphia Positive Chronic Myeloid Leukemia
    • 6.4.2. Hyper-Eosinophilic Syndrome (HES)
    • 6.4.3. Myelodysplastic Syndrome (MDS)
    • 6.4.4. Myeloproliferative Diseases (MPD)
    • 6.4.5. Gastrointestinal Stromal Tumors (GIST)
    • 6.4.6. Others

Chapter 7. Global Imatinib Drug Market, Regional Analysis

  • 7.1. Top Leading Countries
  • 7.2. Top Emerging Countries
  • 7.3. Imatinib Drug Market, Regional Market Snapshot
  • 7.4. North America Imatinib Drug Market
    • 7.4.1. U.S. Imatinib Drug Market
      • 7.4.1.1. Drug Formulation breakdown estimates & forecasts, 2020-2030
      • 7.4.1.2. Application Type breakdown estimates & forecasts, 2020-2030
    • 7.4.2. Canada Imatinib Drug Market
  • 7.5. Europe Imatinib Drug Market Snapshot
    • 7.5.1. U.K. Imatinib Drug Market
    • 7.5.2. Germany Imatinib Drug Market
    • 7.5.3. France Imatinib Drug Market
    • 7.5.4. Spain Imatinib Drug Market
    • 7.5.5. Italy Imatinib Drug Market
    • 7.5.6. Rest of Europe Imatinib Drug Market
  • 7.6. Asia-Pacific Imatinib Drug Market Snapshot
    • 7.6.1. China Imatinib Drug Market
    • 7.6.2. India Imatinib Drug Market
    • 7.6.3. Japan Imatinib Drug Market
    • 7.6.4. Australia Imatinib Drug Market
    • 7.6.5. South Korea Imatinib Drug Market
    • 7.6.6. Rest of Asia Pacific Imatinib Drug Market
  • 7.7. Latin America Imatinib Drug Market Snapshot
    • 7.7.1. Brazil Imatinib Drug Market
    • 7.7.2. Mexico Imatinib Drug Market
  • 7.8. Middle East & Africa Imatinib Drug Market
    • 7.8.1. Saudi Arabia Imatinib Drug Market
    • 7.8.2. South Africa Imatinib Drug Market
    • 7.8.3. Rest of Middle East & Africa Imatinib Drug Market

Chapter 8. Competitive Intelligence

  • 8.1. Key Company SWOT Analysis
    • 8.1.1. Company 1
    • 8.1.2. Company 2
    • 8.1.3. Company 3
  • 8.2. Top Market Strategies
  • 8.3. Company Profiles
    • 8.3.1. Sun Pharmaceutical Industries Ltd.
      • 8.3.1.1. Key Information
      • 8.3.1.2. Overview
      • 8.3.1.3. Financial (Subject to Data Availability)
      • 8.3.1.4. Product Summary
      • 8.3.1.5. Recent Developments
    • 8.3.2. Novartis AG
    • 8.3.3. Dr. Reddy's Laboratories Ltd
    • 8.3.4. Teva Pharmaceutical Industries Ltd.
    • 8.3.5. Mylan N.V.
    • 8.3.6. Cipla Inc
    • 8.3.7. Apotex Inc
    • 8.3.8. Sanofi S.A
    • 8.3.9. Glenmark Pharmaceuticals Ltd.
    • 8.3.10. Dongbao Pharmaceutical Co. Ltd.

Chapter 9. Research Process

  • 9.1. Research Process
    • 9.1.1. Data Mining
    • 9.1.2. Analysis
    • 9.1.3. Market Estimation
    • 9.1.4. Validation
    • 9.1.5. Publishing
  • 9.2. Research Attributes
  • 9.3. Research Assumption